Vertex Ventures HC

Vertex Ventures HC invests in various sectors of the healthcare industry, including biopharmaceuticals, medical devices and digital health.

5.0
(1)
Add your review

Independent rating of Vertex Ventures HC VC fund

Overall rating:
5.0
(1)
Team quality
5.0
Professionalism
Personal qualities
None
Integrity
None
Respect and decency
None
Experience
None
Relevant expertise
None
Investment process
5.0
Approachability
Clarity of the process
None
Speed of the process
None
Responsiveness
Ease of the process
None
Due diligence
None
Value add
Not reviewed
Supportiveness
None
Value add beyond financing
None
Board activity
None
Terms
None
Founder friendly
None
Help with follow-up rounds
None

About Vertex Ventures HC VC fund

Website:
http://vertexventureshc.com/
Founded:
2014
Number of funds:
3
Number of investments:
30
Number of exits:
6
Headquarters:
Palo Alto, United States
Organization type:
Venture Capital

How Vertex Ventures HC VC fund invests

Rounds:
Series B, Series C, Series A
Average ticket size:
27.7M USD
Smallest investment:
9.29M USD
Biggest investment:
75.7M USD
Would lead round:
Yes
Would coinvest:
Yes
Countries where invested:
United States
Sectors of interest:
Health Care, Biotechnology, Therapeutics, Life Science, Pharmaceutical, Biopharma, Medical Device, Medical, Artificial Intelligence

Portfolio - latest investments by Vertex Ventures HC VC fund
NeuSpera Medical
Elevation Oncology
Obsidian Therapeutics
Palleon Pharmaceuticals
BlackThorn Therapeutics
Boundless Bio
Allay Therapeutics
Sonoma BioTherapeutics
Epirium

Founders' reviews of Vertex Ventures HC VC fund

Team quality
5.0
Professionalism
Investment process
5.0
Approachability
Responsiveness
Value add
Not reviewed
Older than a year by non-portfolio founder
Round: Series A
Wholesome Experience
We had a warm intro and it makes all the difference. Putting that to one side, Vertex HC were very responsive and got all of they key decision makers onto a call with us to discuss a potential investment. In the end they didn't invest as we are too early for them but the discussion very in depth and interesting. They gave us some feedback about what they want to see and I am hopeful of trying again in the future.
Similar funds